nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.

ABSTRACT:

Background

Longitudinal data on the impact of treatment on quality of life (QoL) in advanced non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does not deteriorate QoL is key. Here we report longitudinal QoL in patients with squamous NSCLC, receiving ≤4 cycles of nab-paclitaxel/carboplatin combination chemotherapy.

Methods

Patients received nab-paclitaxel 100 mg/m² days 1, 8, 15 + carboplatin area under the curve 6 mg•min/mL day 1 (q3w) for four cycles. QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and Euro-QoL-5 Dimensions-5 Levels (EQ-5D-5L) at baseline and each cycle (day 1).

Results

Two-hundred and six lesion-response-evaluable patients completed baseline + ≥1 postbaseline QoL assessment

SUBMITTER: Thomas M 

PROVIDER: S-EPMC5679693 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature